iSpecimen Inc. (ISPC)

Nasdaq: ISPC · Services-Commercial Physical & Biological Research · Woburn, MA · filing with the SEC since 2012

Full chart Alerts Compare

Grade3.1

◀ Past 1.4● Present 2.5▶ Future 4.7

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of iSpecimen Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.1/10

◀ Past1.425% of the headline

● Present2.535% of the headline

▶ Future4.740% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.3/10

Has it survived what it has been through?

14 warning events since 2017; the latest 2026-09-10.

weight 22% of this tense · 13th percentile among 12 sector filers · read for itself

From the record

iSpecimen Inc.'s filings since 2017 show 14 warning events of 4 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2022-04-29); a notice about its exchange listing (8-K item 3.01, 7 times, the latest 2026-09-10); an auditor change (8-K item 4.01, the latest 2025-03-11); a late-report notice (Form NT 10-K or NT 10-Q, 5 times, the latest 2026-05-18) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

0.9/10

What has it actually done, year after year?

-55.9% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 9th percentile among 12 sector filers · read for its customers

From the record

iSpecimen Inc.'s 3 filed years say what it did: revenue went from $10 million in fiscal 2023 to $2 million in fiscal 2025, down 55.9% a year; it rose in 0 of 2 years; the deepest fall was 81% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

revenue growth over the filed span-55.9%bottom 4% of its family
the share of years revenue rosebottom 4% of its family
the share of filed years with a profitbottom 25% of its family
the deepest fall from a revenue peak80.6%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

2.1/10

How has it treated the people who own it?

SI estimate 2.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 21st percentile among 12 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 21% of 12 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 12 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: iSpecimen Inc.'s shareholder treatment is put at 2.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 21% of 12 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.5/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

2.1/10

Is it financially healthy right now?

ROE -340%: lost 340¢ per shareholder dollar. Leverage 68%: owes 68¢ per asset dollar.

weight 45% of this tense · 21st percentile among 12 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, iSpecimen Inc. lost about 340 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 68 cents per dollar of assets, and net share issuance: its share count grew 547.5% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 38% of its family
return on equitybottom 5% of its family
gross profit against assetsbottom 38% of its family
the share count against the year beforebottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.0/10

How strong is its position in its industry?

bottom 10% of 12 in its family; net margin -543.7%.

weight 22% of this tense · 10th percentile among 12 sector filers · read for its customers

From the record

iSpecimen Inc.'s standing among 12 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 13% by size; a net margin of -543.7% ranks in the bottom 13%; revenue growth of -55.9% a year over the last 2 filed years ranks in the bottom 4% (its annual reports).

What it rests on

revenue against the family$1.9Mbottom 13% of its family
net margin-543.7%bottom 13% of its family
three-year revenue growth-55.9%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

4.0/10

What are the people in charge doing?

SI estimate 4.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 9 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 9 members with one.
What the record cannot read: Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned: family median, 9 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: iSpecimen Inc.'s leadership is put at 4.0 of 10 with a confidence of 20 of 100, because fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title, so the desk assumes the typical reading of its industry family, the median of 9 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.7/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

5.1/10

How much room does it have to grow?

top 49% of 12 in its family for room to expand.

weight 33% of this tense · 51st percentile among 12 sector filers · read for itself

From the record

iSpecimen Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $7 million against no long-term debt tagged leaves 72.2% of its assets as net cash, top 4% of its family; cash from operations less capital spending is -219.9% of revenue (bottom 21%); a gross margin of 1.2% (bottom 38%) (its annual report).

What it rests on

cash less debt against assets72.2%top 4% of its family
cash from operations less capital spending against revenue-219.9%bottom 21% of its family
gross margin1.2%bottom 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.7/10

What could actually drive growth from here?

bottom 47% of 12 in its family for growth drivers.

weight 45% of this tense · 47th percentile among 12 sector filers · read for its customers

From the record

iSpecimen Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -55.9% a year over the last three filed years against -55.9% over all 3, speeding up (top 12% of its family); the newest year grew -79.3% (bottom 4%); research spending grew 19.3% a year (top 6%); capital spending grew -87.2% a year (bottom 4%) (its annual reports). iSpecimen Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 12% of its family
the newest year's revenue growth-79.3%bottom 4% of its family
three-year growth of research spending19.3%top 6% of its family
three-year growth of capital spending-87.2%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

4.1/10

Did its newest year beat what its own record pointed to?

SI estimate 4.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 11 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 11 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 11 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: iSpecimen Inc.'s expectations vs reality is put at 4.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 11 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ISPC · research, not advice